Cost-utility analysis of XXXX extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the @entity195 in the US.

@entity1 @entity716 @entity3393 @entity195
OBJECTIVE: This study evaluates the cost-effectiveness of @entity3393 extended release (ER) as an add-on therapy to acetylcholinesterase inhibitor (AChEI) [combination therapy] for treatment of @entity1 with moderate-to-severe @entity195 ( @entity195 ) from both a healthcare payer and a societal perspective over 3 years when compared to AChEI monotherapy in the US. METHODS: A phase III trial evaluated the efficacy and safety of @entity3393 ER for treatment of @entity195 @entity1 taking an AChEI. The analysis assessed the long-term costs and health outcomes using an individual @entity1 simulation in which @entity195 progression is modeled in terms of cognition, behavior, and functioning changes. Input parameters are based on @entity1 -level trial data, published literature, and publicly available data sources. Changes in anti- @entity716 medication use are incorporated based on a published retrospective cohort study. Costs include drug acquisition and monitoring, total @entity195 -related medical care, and informal care associated with caregiver time. Incremental cost-utility ratio (ICUR), life years, care time for caregiver, time in community and institution, time on anti-psychotics, time by disease severity, and time without severe symptoms are reported. Costs and health outcomes are discounted at 3% per annum. RESULTS: Considering a societal perspective over 3 years, this analysis shows that @entity3393 ER combined with an AChEI provides better clinical outcomes and lower costs than AChEI monotherapy. Discounted average savings were estimated at  18,355 and  20,947 per @entity1 and quality-adjusted life-years (QALYs) increased by an average of 0.12 and 0.13 from a societal and healthcare payer perspective, respectively. @entity1 on combination therapy spent an average of 4 months longer living at home and spend less time in moderate-severe and severe stages of the disease. CONCLUSION: Combination therapy for @entity1 with moderate-to-severe @entity195 is a cost-effective treatment compared to AChEI monotherapy in the US.
